Min Gao

US Patent:

20130195878, Aug 1, 2013

Filed:

Jan 30, 2013

Appl. No.:

13/753836

Inventors:

Min GAO - Montvale NJ, US
Marc R. MORRA - Beacon Falls CT, US
Michael L. LaCROIX-FRALISH - Yorktown Heights NY, US

Assignee:

REGENERON PHARMACEUTICALS, INC. - Tarrytown NY

International Classification:

C07K 16/28

US Classification:

4241391, 5303879

Abstract:

The present invention provides antibodies and antigen-binding fragments thereof that specifically bind to cells expressing acid-sensing ion channel-1 (ASIC1). According to certain embodiments of the invention, the antibodies inhibit acid-induced, ASIC1-mediated ion currents in cells expressing human ASIC1. The antibodies of the invention are useful for the treatment of pain, including pain associated with surgical intervention and various diseases and disorders.

US Patent:

20140056907, Feb 27, 2014

Filed:

Oct 31, 2013

Appl. No.:

14/068173

Inventors:

Min GAO - Montvale NJ, US
Marc R. MORRA - Beacon Falls CT, US
Michael L. LaCROIX-FRALISH - Yorktown Heights NY, US

Assignee:

REGENERON PHARMACEUTICALS, INC. - TARRYTOWN NY

International Classification:

C07K 16/28

US Classification:

4241391, 5303879

Abstract:

The present invention provides antibodies and antigen-binding fragments thereof that specifically bind to cells expressing acid-sensing ion channel-1 (ASIC1). According to certain embodiments of the invention, the antibodies inhibit acid-induced, ASIC1-mediated ion currents in cells expressing human ASIC1. According to certain embodiments, the antibodies of the invention are selective for ASIC1 and do not bind other acid-sensing ion channels in the absence of ASIC1. The antibodies of the invention are useful for the treatment of pain, including pain associated with surgical intervention and various diseases and disorders.

US Patent:

20220411515, Dec 29, 2022

Filed:

Jun 9, 2021

Appl. No.:

17/342749

Inventors:

- Tarrytown NY, US
Min GAO - Montvale NJ, US
Ying HU - Scarsdale NY, US

Assignee:

REGENERON PHARMACEUTICALS, INC. - Tarrytown NY

International Classification:

C07K 16/28
A61K 9/00
A61P 25/00

Abstract:

The present invention provides antibodies that bind specifically to TrkB and methods of using the same. According to certain embodiments, the antibodies of the invention are agonist antibodies that are neuroprotective, as shown by their effect on enhancing the survival of retinal ganglion cells in vitro. As such, these agonist antibodies may be used to treat diseases or disorders of the eye, such as, but not limited to glaucoma. In addition, other neuronal diseases or disorders may benefit from treatment with these agonist antibodies, including any disease or disorder characterized in part by neuronal damage. In certain embodiments, the invention includes antibodies that bind TrkB and mediate cell signaling. The antibodies of the invention may be fully human, non-naturally occurring antibodies.

US Patent:

20220361464, Nov 17, 2022

Filed:

Jun 30, 2022

Appl. No.:

17/810029

Inventors:

- Tarrytown NY, US
Yajun Tang - White Plains NY, US
Jeffrey D. Lee - New York NY, US
Min Gao - Woodcliff Lake NJ, US
Susan D. Croll - New Paltz NY, US
Lynn Macdonald - Harrison NY, US
Ying Hu - Scarsdale NY, US
Carmelo Romano - Tarrytown NY, US

Assignee:

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

International Classification:

A01K 67/027
C12N 9/12
A61K 49/00
C12N 5/10

Abstract:

Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized TRKB locus and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized TRKB locus express a human TRKB protein or a chimeric transthyretin protein, fragments of which are from human TRKB. Methods are provided for using such non-human animals comprising a humanized TRKB locus to assess in vivo efficacy of human-TRKB-targeting reagents such as nuclease agents designed to target human TRKB.

US Patent:

20190159436, May 30, 2019

Filed:

Nov 30, 2018

Appl. No.:

16/206330

Inventors:

- Tarrytown NY, US
Yajun Tang - White Plains NY, US
Jeffrey D. Lee - New York NY, US
Min Gao - Montvale NJ, US
Susan Croll - Putnam Valley NY, US
Lynn Macdonald - Harrison NY, US
Ying Hu - Scarsdale NY, US
Carmelo Romano - Tarrytown NY, US

International Classification:

A01K 67/027
C12N 9/12
A61K 49/00

Abstract:

Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized TRKB locus and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized TRKB locus express a human TRKB protein or a chimeric transthyretin protein, fragments of which are from human TRKB. Methods are provided for using such non-human animals comprising a humanized TRKB locus to assess in vivo efficacy of human-TRKB-targeting reagents such as nuclease agents designed to target human TRKB.

US Patent:

20190161551, May 30, 2019

Filed:

Nov 28, 2018

Appl. No.:

16/202881

Inventors:

- Tarrytown NY, US
Min GAO - Montvale NJ, US
Ying HU - Scarsdale NY, US

Assignee:

REGENERON PHARMACEUTICALS, INC. - Tarrytown NY

International Classification:

C07K 16/28
A61K 9/00
A61P 25/00

Abstract:

The present invention provides antibodies that bind specifically to TrkB and methods of using the same. According to certain embodiments, the antibodies of the invention are agonist antibodies that are neuroprotective, as shown by their effect on enhancing the survival of retinal ganglion cells in vitro. As such, these agonist antibodies may be used to treat diseases or disorders of the eye, such as, but not limited to glaucoma. In addition, other neuronal diseases or disorders may benefit from treatment with these agonist antibodies, including any disease or disorder characterized in part by neuronal damage. In certain embodiments, the invention includes antibodies that bind TrkB and mediate cell signaling. The antibodies of the invention may be fully human, non-naturally occurring antibodies.

US Patent:

20180222976, Aug 9, 2018

Filed:

Sep 28, 2017

Appl. No.:

15/719220

Inventors:

- Tarrytown NY, US
Min Gao - Montvale NJ, US
Marc R. Morra - Beacon Falls CT, US
Nicole M. Alessandri-Haber - Rye NY, US
Michael L. LaCroix-Fralish - Yorktown Heights NY, US

International Classification:

C07K 16/28
C07K 16/18
A61K 39/00

Abstract:

The present invention provides antibodies and antigen-binding fragments thereof that specifically bind to cells expressing acid-sensing ion channel-1 (ASIC1). According to certain embodiments of the invention, the antibodies inhibit acid-induced, ASIC1-mediated ion currents in cells expressing human ASIC1. The antibodies of the invention are useful for the treatment of pain, including pain associated with surgical intervention and various diseases and disorders.

US Patent:

20160002332, Jan 7, 2016

Filed:

Sep 9, 2015

Appl. No.:

14/848452

Inventors:

- Tarrytown NY, US
Min Gao - Montvale NJ, US
Marc R. Morra - Beacon Falls CT, US
Nicole M. Alessandri-Haber - Rye NY, US
Michael L. LaCroix-Fralish - Yorktown Heights NY, US

International Classification:

C07K 16/28

Abstract:

The present invention provides antibodies and antigen-binding fragments thereof that specifically bind to cells expressing acid-sensing ion channel-1 (ASIC1). According to certain embodiments of the invention, the antibodies inhibit acid-induced, ASIC1-mediated ion currents in cells expressing human ASIC1. The antibodies of the invention are useful for the treatment of pain, including pain associated with surgical intervention and various diseases and disorders.